Katharine Bradley, MD, MPH
Kaiser Permanente Washington Health Research Institute
Sean Murphy, PhD
Weill Cornell Medicine
Effective treatment for opioid use disorder (OUD) has been shown to improve patient outcomes and reduce health care costs; however, evidence of this effect in primary care settings is severely limited. The health economic findings from this study will supplement the parent PROUD trial’s results regarding clinical effectiveness and implementation outcomes and provide critical contextual information for health systems and other healthcare stakeholders. The study wille valuate the economic viability of the PROUD collaborative care model for OUD; that is, from the perspective of the health care sector, to what extent do the downstream cost savings associatd with improved patient outcomes offset the additional costs of the PROUD intervention. The specific aims are to: 1) estimate the start-up and ongoing management costs of the PROUD intervention; 2) assess costs associated with health care utilization for patients who receive primary care treatment in PROUD and usual care clinics and have been identified with recognized OUD prior to clinic randomization; 3) estimate the economic value of the PROUD intervention, measured as net monetary benefit (NMB, incremental benefit-incremental cost), from the health care sector perspective.
Funded by the NIH HEAL InitiativeSM.
All Participating Nodes: